hotspot -WSS

hotspot

author：entertainment 2025-09-06 01:59:44 - browse：99

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — A newly approved Alzheimer’s drug made by Eisai and Biogen, called Leqembi, aims to clear out amyloid plaques in patients’ brains. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

WASHINGTON — Medicare on Monday proposed ending restrictions on how many PET scans patients can receive to detect amyloid plaques in their brains, which will offer physicians more options as they treat patients with a new drug to slow the progression of dementia.

The agency that oversees Medicare had previously restricted coverage to a single scan for patients who participated in clinical studies. Advocates had warned that could cause issues related to a new class of Alzheimer’s drugs designed to clear those plaques.

“We know there is significant interest in the medical community about new treatments that may be effective in slowing the development of Alzheimer’s disease. PET scans are an important part of diagnosis and treatment of Alzheimer’s disease,” Centers for Medicare and Medicaid Administrator Chiquita Brooks-LaSure said in a written statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： The problem with charging patients to message their doctors

WSS

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Headspace, Meta partner to launch VR meditation app for Quest

Arc Institute generative AI designs new CRISPR systems

Readers respond to H5N1 and livestock movements, and more

NEJM study link tiny plastics in blood vessels to heart problems

Case highlights the risks of experimental stem cell therapy

explore

hotspot

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

With psoriasis trial ahead, Alumis raises $259 million

Jerome Adams on the need for new antivirals for Covid

Solving academic medical centers' existential crisis

Alkermes shareholders re

Change Healthcare cyberattack prompts Medicare loan program

Hollywood unions extend contract negotiations for actors

A deep dive into Applied Therapeutics’ data, and questions on Cassava

BioMarin wins approval for gene therapy to treat hemophilia A

Data integrity in scientific journals requires "effort" by publishers, institutions

focus

Change Healthcare cyberattack prompts Medicare loan program

Case highlights the risks of experimental stem cell therapy

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Sen. Paul opposes bill to ban Chinese biotechs

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

HIV vaccine remains elusive. Immunologists keep trying new ideas

focus

Wikipedia

focus

focus